Alliance Global Lowers Pluristem Therapeutics' Price Target to $4 From $9.50, Maintains Buy Rating
Pluristem Therapeutics Price Target Cut to $4.00/Share From $9.50 by Alliance Global Partners
Pluristem Therapeutics Is Maintained at Buy by Alliance Global Partners
Pluristem Therapeutics analyst ratings
Alliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4